Liquid Biopsy for ALK-Positive Early Non-Small-Cell Lung Cancer Predicts Disease Relapse

References

• Chia PL , MitchellP, DobrovicA, JohnT. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin. Epidemiol.6, 423 (2014).
   PubMed Web of Science ®Google Scholar
• Zhou W , ChristianiDC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin. J. Cancer.30(5), 287 (2011).
   PubMedGoogle Scholar
• Carlson JJ , SuhK, OrfanosP, WongWJP. Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Clin. Drug Investig.36(4), 495–504 (2018).
   Google Scholar
• Awad MM , ShawAT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin. Adv. Hematol. Oncol.12(7), 429–439 (2014).
   PubMedGoogle Scholar
• Shaw AT , YeapBY, Mino-KenudsonMet al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol.27(26), 4247 (2009).
   PubMed Web of Science ®Google Scholar
• Doebele RC , PillingAB, AisnerDLet al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res.18(5), 1472–1482 (2012).
   PubMed Web of Science ®Google Scholar
• Sawada S , SuehisaH, UenoTet al. Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography. Lung Cancer (Auckl).7, 45–51 (2016).
   PubMedGoogle Scholar
• Choi SH , KimYT, KimSKet al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann. Thorac. Surg.92(5), 1826–1832 (2011).
   PubMed Web of Science ®Google Scholar
• Chia PL , MitchellP, DobrovicA, JohnTJCE. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin. Epidemiol.6, 423 (2014).
   PubMed Web of Science ®Google Scholar
• Younes RN , GrossJL, DeheinzelinDJC. Follow-up in lung cancer: how often and for what purpose?115(6), 1494–1499 (1999).
   Google Scholar
• Ilié M , HofmanP. Pros:can tissue biopsy be replaced by liquid biopsy?Transl. Lung Cancer Res.5(4), 420 (2016).
   PubMed Web of Science ®Google Scholar
• Alix-Panabières C , PantelK. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov.6(5), 479–491 (2016).
   PubMed Web of Science ®Google Scholar
• Pantel K , Alix-PanabieresC. Liquid biopsy: Potential and challenges. Mol. Oncol.10(3), 371–373 (2016).
   PubMed Web of Science ®Google Scholar
• Pailler E , AdamJ, BarthelemyAet al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J. Clin. Oncol.31(18), 2273–2281 (2013).
   PubMed Web of Science ®Google Scholar
• He W , XuD, WangZet al. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma. J. Transl. Med.17(1), 32 (2019).
   PubMedGoogle Scholar
• Pailler E , OulhenM, BorgetIet al. Circulating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK-rearranged non-small cell lung cancer patients. Cancer Res.77(9), 2222–2230 (2017).
   PubMed Web of Science ®Google Scholar
• Imamura F , UchidaJ, KukitaYet al. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer94, 68–73 (2016).
   PubMed Web of Science ®Google Scholar
• Chabon JJ , SimmonsAD, LovejoyAFet al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun.7(1), 1–15 (2016).
   Google Scholar
• Tan CL , LimTH, LimTKet al. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. Oncotarget7(17), 23251 (2016).
   PubMedGoogle Scholar
• Zhang Z , ShiratsuchiH, PalanisamyNet al. Expanded circulating tumor cells from a patient with ALK-positive lung cancer present with EML4-ALK rearrangement along with resistance mutation and enable drug sensitivity testing: a case study. J. Thorac. Oncol.12(2), 397–402 (2017).
   PubMed Web of Science ®Google Scholar
• Kidess-Sigal E , LiuHE, TribouletMMet al. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget7(51), 85349 (2016).
   PubMedGoogle Scholar
• Moreno JG , O’HaraSM, GrossSet al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology58(3), 386–392 (2001).
   PubMed Web of Science ®Google Scholar
• Hartkopf AD , WagnerP, WallwienerDet al. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res.31(3), 979–984 (2011).
   PubMed Web of Science ®Google Scholar
• Tan K , LeongSM, KeeZet al. Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients. Cancer Lett.423, 1–8 (2018).
   PubMed Web of Science ®Google Scholar
• Yang B , QinA, ZhangKet al. Circulating tumor cells predict prognosis following tyrosine kinase inhibitor treatment in EGFR-mutant non-small cell lung cancer patients. Oncol. Res.25(9), 1601–1606 (2017).
   PubMed Web of Science ®Google Scholar
• Tong B , XuY, ZhaoJet al. Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer. Thorac. Cancer9(5), 640–645 (2018).
   PubMed Web of Science ®Google Scholar
• Lee Y , ParkS, KimWSet al. Correlation between progression–free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced–stage EGFR–mutated non–small cell lung cancer. Thorac. Cancer9(9), 1104–1110 (2018).
   PubMed Web of Science ®Google Scholar